全关节置换后钴中毒的F-18 FDG PET脑成像表现
本研究对247例含钴铬合金关节置换患者筛查血/尿钴水平,对123例超标者中69例有症状者行F-18 FDG PET脑定量分析。结果显示扫描患者均存在显著区域代谢减低,以颞叶、额叶、Broca区等为主,15例翻修术后8例代谢改善。提示现行钴暴露阈值可能需要修订。
要点
- 血钴>0.4 mcg/L或尿钴>1 mcg/L的有症状关节置换患者应警惕神经毒性。
- F-18 FDG PET脑定量分析可显示颞叶、额叶等区域代谢减低模式。
- 翻修术后部分患者脑代谢可改善,PET可能辅助手术时机决策。
核心结论
- 所有扫描患者均存在显著区域脑代谢减低,提示系统性钴水平升高所致神经毒性存在特定区域易感模式。
- 该模式与重金属及溶剂脑病相似,不同于经典痴呆,且可能在血钴0.4 mcg/L、尿钴1 mcg/L时即出现。
- 现行钴暴露与监测阈值可能需要修订,定量F-18 FDG PET脑成像可能辅助治疗选择与手术时机决策。
研究设计与样本
- 48个月内连续筛查247例含钴铬合金关节置换患者,检测全血和尿钴水平并采用10项症状量表评估。
- 血钴>0.4 mcg/L或尿钴>1 mcg/L的有症状患者接受F-18 FDG PET脑成像,采用FDA批准的定量脑分析软件,以脑桥为参考区。
主要发现
- 247例筛查患者中123例血和尿钴水平超过阈值,69例接受扫描者存在统计学显著的区域代谢减低且症状量表评分更高。
- 代谢减低分布依次为颞叶、额叶、Broca区、前扣带回、顶叶、后扣带回、视觉区、感觉运动区、丘脑,最后为尾状核。
- 金属对金属(MoM)与金属对塑料(MoP)关节置换产生相似的代谢减低模式。
- 15例接受必要翻修手术的患者中,8例再次扫描时显示代谢改善。
关键数值与推荐
- 血钴水平>0.4 mcg/L或尿钴>1 mcg/L作为有症状患者进一步行脑PET成像的阈值。
- 采用FDA批准的定量脑分析软件,以脑桥为参考区进行脑代谢分析。
- 症状评估采用临床验证的10项症状量表。
临床怎么用
- 对含钴铬合金关节置换且出现记忆减退、执行功能下降、震颤、听力视力丧失、抑郁等症状的患者,应检测血和尿钴水平。
- 血钴>0.4 mcg/L或尿钴>1 mcg/L的有症状患者可考虑行F-18 FDG PET脑定量分析评估代谢减低程度与模式。
- PET所示区域代谢减低模式可能辅助鉴别钴神经毒性与其他原因痴呆,并为翻修手术时机提供参考。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Imaging studies of cobalt toxicity from cobalt-chromium alloy arthroprosthetics have focused on the local intra-articular and peri-articular presentation from failing joint replacements. Most studies investigating neurological findings have been small case series focused on the clinical findings of memory loss, diminished executive function, tremor, hearing and vision loss, depression, and emotional lability. This study utilizes software-based quantitative analysis of brain metabolism to assess the degree of hypometabolism and areas of susceptibility, determine if a pattern of involvement exists, and measure reversibility of findings after prosthetic revision to cobalt-free appliances. METHODS: Over 48 months, 247 consecutive patients presenting to an orthopedic clinic with an arthroprosthetic joint containing any cobalt-chromium part were screened with whole blood and urine cobalt levels. A clinically validated inventory of 10 symptoms was obtained. Symptomatic patients with a blood cobalt level above 0.4 mcg/L or urine cobalt greater than 1 mcg/L underwent F-18 FDG PET brain imaging. Analysis was performed with FDA-approved quantitative brain analysis software with the pons as the reference region. Control group was the normal brain atlas within the software. RESULTS: Of the 247 consecutively screened patients, 123 had blood and urine cobalt levels above the threshold. The 69 scanned patients had statistically significant regional hypometabolism and higher symptoms inventory. Fifty-seven patients were retained in the study. Distribution of hypometabolism was in descending order: temporal, frontal, Broca's areas, anterior cingulate, parietal, posterior cingulate, visual, sensorimotor, thalamic, and lastly caudate. Metal-on-metal (MoM) and metal-on-plastic (MoP) joint replacements produced similar patterns of hypometabolism. Of 15 patients with necessary revision surgery, 8 demonstrated improved metabolism when later re-scanned. CONCLUSION: All scanned patients had regions of significant hypometabolism. Neurological toxicity from elevated systemic cobalt levels following arthroprosthetic joint replacement has a pattern of regional susceptibility similar to heavy metals and solvents, differing from classical dementias and may occur at blood and urine cobalt levels as low as 0.4 mcg/L and 1 mcg/L, respectively. Presently accepted thresholds for cobalt exposure and monitoring may need revision. Quantitative F-18 FDG PET brain imaging may aid in the decision process for treatment options and timing of possible medical versus surgical intervention.
引用
- Bridges RL, Cho CS, Beck MR, et al. F-18 FDG PET brain imaging in symptomatic arthroprosthetic cobaltism. Eur J Nucl Med Mol Imaging. 2019. PMID: 31863138. doi:10.1007/s00259-019-04648-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。